Table 1.
Prognostic factors for developing cGVHD
|
All patients, N = 404
|
|||||
|---|---|---|---|---|---|
| Development of cGVHD | CINC of cGVHD at 2 years | 95% CI | Hazard ratio* | P | Favorable factors |
| Treatment arm | |||||
| M/C | 0.34 | 0.27-0.40 | 1.22 | .27 | NA |
| TCD | 0.29 | 0.22-0.35 | 1.00 | NA | NA |
| Acute GVHD grade† | No prior aGVHD (0-I) | ||||
| II-IV | NA | NA | 1.84 | < .01 | NA |
| 0-I | NA | NA | 1.00 | NA | NA |
| Recipient age | Younger recipients | ||||
| Less than 19 years | 0.23 | 0.14-0.32 | 1.00 | NA | NA |
| 18-35 years | 0.35 | 0.27-0.43 | 2.51 | < .01 | NA |
| Greater than 35 years | 0.32 | 0.25-0.40 | 2.44 | < .01 | NA |
| Primary disease | Diseases other than CML | ||||
| CML | 0.40 | 0.33-0.48 | 1.75 | < .01 | NA |
| Other | 0.23 | 0.18-0.29 | 1.00 | NA | NA |
| CD34+, infused/kg (× 106) | Higher CD34+ infused | ||||
| Less than or equal to 2.0 | 0.34 | 0.27-0.41 | 1.73 | < .01 | NA |
| Greater than 2.0 | 0.28 | 0.22-0.35 | 1.00 | NA | NA |
Variables that were considered and found not significant were date of transplantation, center, Karnofsky-Lansky performance status, sex of recipient and donor, donor age, HLA match, risk status, recipient and donor CMV status, recipient and donor race, method of T-cell depletion, T cells infused/kg, and total nucleated cell dose infused/kg.
NA indicates not applicable.
*
Cox proportional hazards univariate analysis
†
Point estimates for aGVHD are not presented since it is a time-varying covariate